

Fm PTC-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 018733/1060	SERIAL NO. 09/1965796 Unassigned
INFORMATION DISCLOSURE CITATION		APPLICANT David M. GOLDENBERG	
Submitted October 1, 2001 (Use several sheets if necessary)		FILING DATE October 1, 2001	GROUP ART UNIT 1642 Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
amh	A1	5,686,072	02/1994	Uhr et al.			
amh	A2	5,484,892	01/1996	Tedder et al.			
	A3	5,686,072	11/11/97	Uhr et al.	DUPPLICATE REFERENCE / SAME AS A1		

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
amh	A4	EP 510 949 A2	04/1992	Europe				
	A5	WO 95/09917	04/1995	WO				
	A6	WO 98/42378	01/1998	WO				
↓	A7	WO 99/02567	01/1999	WO				
↓	A8	WO 96/04925	02/1996	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

amh	A9	S. Kiesel et al. "Removal of Cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement..." Leukemia Research vol. II, no. 12, 1987, pages 1119-1125
		O. Press, "Prospects for the management on non-Hodgkin's lymphomas with monoclonal antibodies and Immunoconjugates." Cancer Journal from Scientific American, vol. 4, no. suppl. 2, July 1998.
amh	A11	D. Maloney et al. "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal Antibody (IDE-C2B8) in patients with recurrent B-cell lymphoma" Blood, vol. 84, no. 8, 1994, pages 2457-2466.
		M. Ghetie et al. "A Combination of immunotoxins and chemotherapy can cure SCID mice of Human B-Cell Tumors" The Faseb Journal, vol. 8, no. 4, 1994.
amh	A13	D. Flavell et al., "Systematic Therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-Saporin Immunotoxin, is curative of human B-Cell..." Cancer Research, vol. 57, no. 21, 1997 Nov, pages 4824-9.
		Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with hum.Ig heavy and light Chain YACS", Nature Genetic, vol. 7, pp. 13-21, volume 1, May 1994.
amh	A15	R. French et al., "Response of B-cell lymphoma to a combination of bispecific antibodies and saporin"
		Leukemia Research, vol. 20, no. 7, July 1996, pages 607-617.

EXAMINER	amh	DATE CONSIDERED	01/06/2004
----------	-----	-----------------	------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/1060	SERIAL NO. 09/965,796 <u>Unassigned</u>		
INFORMATION DISCLOSURE CITATION				APPLICANT David M. GOLDENBERG			
Submitted October 1, 2001 (Use several sheets if necessary)				FILING DATE October 1, 2001	GROUP ART UNIT 1642 <u>Unassigned</u>		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>amh</i>	A16	C. Renner et al. "Monoclonal antibodies in the treatment of non-Hodgkin's Lymphoma: recent results and Future Prospects" Leukemia, Vol. 11, no. suppl.2, April 1997, 555-59.					
	A17	J. Leonard et al. "Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results" Blood, vol. 94, no. 10-suppl.-1-part.1., 1999.					
<i>amh</i>	A18	Kaminski et al., "Radioimmunotherapy of B-Cell lymphoma with [131] Anti-B1 [Anti-CD20] Antibody", New England J. of Medicine 329(7): 459-465, August 12, 1993.					
	A19	Vuist et al., "Potentiation by interleukin 2 of burkitt's lymphoma therapy with Anti-Pan B (Anti-CD19) monoclonal antibodies in a mouse xenotransplantation model", Cancer Research, Vol 53, pp 819-825					
<i>amh</i>	A20	Juweid et al., "Treatment of non-hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22", Cancer Research (Suppl.) Vol. 55, pp 5899s-5907s, December 1, 1995.					
<i>amh</i>	A21	Kreitman, R. et.al. Pseudomonas Exotoxin-based Immunotoxins Containing the Antibody LL2 or LL2-Fab' Induce Regression of Subcutaneous Human B-Cell Lymphomas in Mice, Cancer Research 53: 819-825, February 15, 1993.					
EXAMINER	<i>Amh Harris</i>			DATE CONSIDERED <i>01/06/2004</i>			
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>							